Article
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Medical oncology (Northwood, London, England) - 1 Oct 2014
Moiseyenko Vladimir M, Chubenko Vyacheslav A, Moiseyenko Fedor V, Zhabina Albina S, Gorodnova Tatiana V, Komarov Yuri I, Bogdanov Alexey A, Sokolenko Anna P, Imyanitov Evgeny N
Abstract excerpt
Ovarian carcinomas (OC) arising in BRCA1 and BRCA2 mutation carriers demonstrate pronounced sensitivity to platinum-based therapy due to deficiency of double-strand break DNA repair. However, the choice of subsequent treatment lines for this category of women remains complicated. We considered mitomycin C for heavily pretreated hereditary OC patients, based on multiple evidence for BRCA-specific activity of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.